Market Research Logo

70 kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) - Pipeline Review, H2 2016

70 kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘70 kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) - Pipeline Review, H2 2016’, provides in depth analysis on 70 kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) targeted pipeline therapeutics.

The report provides comprehensive information on the 70 kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in 70 kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

  • The report provides a snapshot of the global therapeutic landscape for 70 kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1)
  • The report reviews 70 kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in 70 kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses 70 kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to 70 kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) targeted therapeutics
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for 70 kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding 70 kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Introduction
Global Markets Direct Report Coverage
70 kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) Overview
Therapeutics Development
70 kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) - Products under Development by Stage of Development
70 kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) - Products under Development by Therapy Area
70 kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) - Products under Development by Indication
70 kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) - Pipeline Products Glance
Late Stage Products
Early Stage Products
70 kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) - Products under Development by Companies
70 kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) - Therapeutics Assessment
Assessment by Monotherapy/Combination Products
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
70 kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) - Companies Involved in Therapeutics Development
ArQule, Inc.
Astex Pharmaceuticals Inc
Eddingpharm
Merck KGaA
PharmAust Limited
Phoenix Biotechnology, Inc.
Sentinel Oncology Limited
70 kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) - Drug Profiles
AT-13148 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EDP-317 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
M-2698 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
monepantel - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PBI-05204 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule To Inhibit S6K1 For Breast Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit S6K for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
70 kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) - Dormant Projects
70 kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) - Discontinued Products
70 kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) - Featured News & Press Releases
Jul 11, 2016: Juniper Pharma Successfully Completes Manufacture of Reformulated MPL Capsules
Jan 29, 2016: PharmAust Limited Announced Quarterly Report & Company Update For the period ended 31 December 2015
Nov 26, 2015: PharmAust Appoints GenScript to Complete Further Pre-Clinical Validation for Phase II Trial
Jan 17, 2013: Cancer Research UK And Cancer Research Technology Launches Phase I Clinical Trial With AT13148 To Treat Several Cancer Types
Jan 16, 2013: Astex Pharma Announces Cancer Research UK And Cancer Research Technology Initiate AT13148 Clinical Trial To Treat Several Cancer Types
Jul 10, 2012: Experimental Drug Could Treat Different Cancers, New Research Says
Jan 22, 2010: ACT BIOTECH Announces FDA Acceptance Of IND For ACTB1003, A First-in-Class Anti-Cancer Therapeutic
Oct 18, 2007: Astex Drug Candidates To Be Featured At The 2007 AACR-NCI-EORTC International Conference
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for, H2 2016
Number of Products under Development by Therapy Area, H2 2016
Number of Products under Development by Indication, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Number of Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016
Assessment by Monotherapy/Combination Products, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Pipeline by ArQule, Inc., H2 2016
Pipeline by Astex Pharmaceuticals Inc, H2 2016
Pipeline by Eddingpharm, H2 2016
Pipeline by Merck KGaA, H2 2016
Pipeline by PharmAust Limited, H2 2016
Pipeline by Phoenix Biotechnology, Inc., H2 2016
Pipeline by Sentinel Oncology Limited, H2 2016
Dormant Projects, H2 2016
Discontinued Products, H2 2016
List of Figures
Number of Products under Development for, H2 2016
Number of Products under Development by Therapy Area, H2 2016
Number of Products under Development by Indication, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy/Combination Products, H2 2016
Number of Products by Stage and Mechanism of Actions, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report